Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. addia

ADDIA SIGNED

Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ADDIA project word cloud

Explore the words cloud of the ADDIA project. It provides you a very rough idea of what is the project "ADDIA" about.

registered    alzheimer    400    quality    biomarkers    centres    probes    questionable    economy    exists    autopsy    market    performance    procedure    treatment    ce    clinical    blood    annually    organisation    diagnosis    flow    single    neuropsychological    fluid    performing    invasive    meet    proven    combination    human    addia    puncture    amounts    patients    life    validate    drug    tests    diagnostics    lumbar    committed    million    america    cytometry    800    successful    property    previously    kit    diagnostic    expensive    consequently    cerebrospinal    formally    ivd    efficacy    sme    patient    diagnose    examination    risky    holds    monitoring    definite    fluorescent    ad    japan    biomarker    months    proof    medical    french    inexpensive    pop    urgent    amoneta    disease    innovative    subjects    fast    commercialization    weeks    small    introduction    enrol    performed    ready    detect    2    scientifically    validated    usually    assay    imaging    healthcare    intellectual    initial    diagnosed    company    brain   

Project "ADDIA" data sheet

The following table provides information about the project.

Coordinator		 AMONETA DIAGNOSTICS 

Organization address
address: 17 RUE DU FORT
city: HUNINGUE
postcode: 68330
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.addia-project-h2020.eu
 Total cost 4˙998˙625 €
 EC max contribution 4˙998˙625 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-08-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AMONETA DIAGNOSTICS FR (HUNINGUE) coordinator 4˙998˙625.00

Map

 Project objective

The French SME Amoneta Diagnostics has previously developed a diagnostic kit for Alzheimer’s disease (AD) based on two blood biomarkers that are scientifically proven to be associated with AD. The company holds the intellectual property for specific fluorescent probes that can detect these biomarkers in small amounts of blood using flow cytometry. Currently, no single test to diagnose AD exists. A potential AD diagnosis is usually given by a combination of clinical examination, neuropsychological tests and brain imaging over weeks/months. A lumbar puncture can be performed to detect biomarkers in cerebrospinal fluid, but this procedure is risky and expensive. A definite AD diagnosis can formally only be given by autopsy. Consequently, the diagnosis is assessed late and still questionable. The novel kit allows the diagnosis of AD, using only one single test, in a fast, non-invasive and inexpensive way. We expect the blood-based biomarker kit to facilitate assessment of drug efficacy in AD drug development and the monitoring of treatment efficacy in AD patients. This kit will meet the urgent medical need of ~2 million patients in Europe, Japan and America, that are annually diagnosed with AD. Successful implementation will have a strong impact on the quality of life of patients and a significant impact on the healthcare system and economy. In this project, Amoneta Diagnostics will validate this diagnostic test by performing a Proof-of-Performance (PoP) clinical study in 800 human subjects including 400 AD patients. At the end of this 3-year project, a validated and CE registered IVD biomarker assay will be available and ready for clinical application. This innovative ADDIA biomarker assay will be ready for initial market introduction and further commercialization and implementation. The project is supported by patient organisation Alzheimer Europe, and several leading European Alzheimer centres that are committed to enrol subjects for the PoP clinical study.

 Deliverables

List of deliverables.
Scientific papers prepared for peer-reviewed open access journals Documents, reports 2019-11-11 10:17:23
Letters and project updates to patient organisation Alzheimer Europe Documents, reports 2019-11-11 10:17:23

Take a look to the deliverables list in detail:  detailed list of ADDIA deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Bruno Dubois, MD, PhD, Professor, Jean-Christophe Bier, MD, Frederic Blanc, MD, PhD, Renaud David, MD, PhD, Jean-François Démonet, MD, PhD, Hüseyin Firat, MD, PhD, Giovanni B Frisoni, Prof, PhD, MD, Audrey Gabelle, MD, PhD, Hakan I. Gurvit, MD, Adrian Ivanoiu, MD, PhD, Eloi Magnin, MD, PhD, Moira Marizzoni, PhD, Saliha Moussaoui, PhD, Florence Pasquier, MD PhD and François Sellal, MD
Addia, a Multi- Center Clinical Study of Proof-of-Performance to Validate Blood-BasedBiomarkers for the Diagnostic of Alzheimer’s Disease (AD): The Study Protocol.
published pages: , ISSN: , DOI: 		2019-08-29
2019 F. Blanc, F. Giovanni, M. Marizzoni, C. Mutter, J.C. Bier, F. Sellal, J.F. Démonet, S. Boutillier, H. Firat, S. Moussaoui, R. David, A. Ivanoiu, E. Magnin, A. Gabelle, F. Pasquier, H. Gurvit, B. Dubois
ADDIA Chronobiology Study and Proof-of-Performance Study to Validate Blood-Based Biomarkers for the Diagnostic of early Alzheimer’s Disease (AD)
published pages: , ISSN: , DOI: 		2019-08-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADDIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADDIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More